Entrada Therapeutics (NASDAQ: TRDA) insider transactions
In the twelve months to 10 November 2026, executives and directors of Entrada Therapeutics reported 44 open-market sales of 1,934,700 shares ($15.1m) and 13 open-market purchases of 181,037 shares ($1.4m), by 15 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 9 September 2026 | Mpm Bioventures 2018 (b), L.p. | — | Open-market sale | −28,837 | $7.13 | 3,885,115 | Form 4 |
| 9 September 2026 | MPM BioVentures 2018 GP LLC | — | Open-market sale | −28,837 | $7.13 | 3,885,115 | Form 4 |
| 8 September 2026 | Mpm Bioventures 2018 (b), L.p. | — | Open-market sale | −192,500 | $7.41 | 3,913,952 | Form 4 |
| 8 September 2026 | MPM BioVentures 2018 GP LLC | — | Open-market sale | −192,500 | $7.41 | 3,913,952 | Form 4 |
| 4 September 2026 | Mpm Bioventures 2018 (b), L.p. | — | Open-market sale | −38,500 | $7.11 | 4,106,452 | Form 4 |
| 4 September 2026 | MPM BioVentures 2018 GP LLC | — | Open-market sale | −38,500 | $7.11 | 4,106,452 | Form 4 |
| 3 September 2026 | MPM BioVentures 2014 GP LLC | — | Open-market sale | −32,263 | $7.17 | 4,144,952 | Form 4 |
| 3 September 2026 | MPM BioVentures 2018 LLC | — | Open-market sale | −32,263 | $7.17 | 4,144,952 | Form 4 |
| 2 September 2026 | MPM BioVentures 2014 GP LLC | — | Open-market sale | −25,131 | $7.19 | 4,177,215 | Form 4 |
| 2 September 2026 | MPM BioVentures 2018 LLC | — | Open-market sale | −25,131 | $7.19 | 4,177,215 | Form 4 |
| 2 September 2026 | Doshi Dipal | CEO | Shares withheld for tax | −8,724 | $7.14 | 517,290 | Form 4 |
| 2 September 2026 | Wentworth Kory James | Chief Financial Officer | Shares withheld for tax | −1,733 | $7.14 | 117,277 | Form 4 |
| 2 September 2026 | Dowden Nathan J | President & COO | Shares withheld for tax | −2,528 | $7.14 | 196,060 | Form 4 |
| 2 September 2026 | Sethuraman Natarajan | President, Research & Develop. | Shares withheld for tax | −2,079 | $7.14 | 214,238 | Form 4 |
| 1 September 2026 | MPM BioVentures 2014 GP LLC | — | Open-market sale | −29,088 | $7.06 | 4,202,346 | Form 4 |
| 1 September 2026 | MPM BioVentures 2018 LLC | — | Open-market sale | −29,088 | $7.06 | 4,202,346 | Form 4 |
| 31 August 2026 | MPM BioVentures 2014 (B), L.P. | — | Open-market sale | −44,259 | $6.99 | 4,231,434 | Form 4 |
| 31 August 2026 | MPM BioVentures 2018 LLC | — | Open-market sale | −44,259 | $6.99 | 4,231,434 | Form 4 |
| 28 August 2026 | MPM BioVentures 2014 (B), L.P. | — | Open-market sale | −3,733 | $7.01 | 4,275,693 | Form 4 |
| 28 August 2026 | MPM BioVentures 2018 LLC | — | Open-market sale | −3,733 | $7.01 | 4,275,693 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Entrada Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.